CN109601987A - 一种微胶囊粉、乳母营养补充食品及其制备方法 - Google Patents
一种微胶囊粉、乳母营养补充食品及其制备方法 Download PDFInfo
- Publication number
- CN109601987A CN109601987A CN201910067182.7A CN201910067182A CN109601987A CN 109601987 A CN109601987 A CN 109601987A CN 201910067182 A CN201910067182 A CN 201910067182A CN 109601987 A CN109601987 A CN 109601987A
- Authority
- CN
- China
- Prior art keywords
- parts
- slurries
- microcapsule powder
- wet nurse
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 63
- 239000000843 powder Substances 0.000 title claims abstract description 61
- 239000003094 microcapsule Substances 0.000 title claims abstract description 53
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 34
- 235000009496 Juglans regia Nutrition 0.000 claims abstract description 33
- 235000020234 walnut Nutrition 0.000 claims abstract description 33
- 239000000126 substance Substances 0.000 claims abstract description 25
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims abstract description 23
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract description 22
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims abstract description 22
- 235000016709 nutrition Nutrition 0.000 claims abstract description 21
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 20
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 20
- 239000005862 Whey Substances 0.000 claims abstract description 18
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229920001353 Dextrin Polymers 0.000 claims abstract description 17
- 239000004375 Dextrin Substances 0.000 claims abstract description 17
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 17
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 17
- 235000019425 dextrin Nutrition 0.000 claims abstract description 17
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 16
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 16
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 16
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 16
- 239000011709 vitamin E Substances 0.000 claims abstract description 16
- 229940046009 vitamin E Drugs 0.000 claims abstract description 16
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims abstract description 15
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 claims abstract description 13
- 229940108924 conjugated linoleic acid Drugs 0.000 claims abstract description 13
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 12
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical class OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 10
- 239000002002 slurry Substances 0.000 claims description 57
- 241000758789 Juglans Species 0.000 claims description 32
- 238000002156 mixing Methods 0.000 claims description 28
- 239000002994 raw material Substances 0.000 claims description 16
- 238000010438 heat treatment Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 235000018102 proteins Nutrition 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000001694 spray drying Methods 0.000 claims description 13
- 238000001816 cooling Methods 0.000 claims description 12
- 230000035764 nutrition Effects 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 10
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 10
- 229930195729 fatty acid Natural products 0.000 claims description 10
- 239000000194 fatty acid Substances 0.000 claims description 10
- 150000004665 fatty acids Chemical class 0.000 claims description 10
- 235000020778 linoleic acid Nutrition 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 9
- 238000010008 shearing Methods 0.000 claims description 9
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 8
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 8
- 229960004488 linolenic acid Drugs 0.000 claims description 8
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 8
- 108060003951 Immunoglobulin Proteins 0.000 claims description 7
- 238000000889 atomisation Methods 0.000 claims description 7
- 102000018358 immunoglobulin Human genes 0.000 claims description 7
- 238000005507 spraying Methods 0.000 claims description 7
- 108010063045 Lactoferrin Proteins 0.000 claims description 6
- 102000010445 Lactoferrin Human genes 0.000 claims description 6
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 6
- 235000021242 lactoferrin Nutrition 0.000 claims description 6
- 229940078795 lactoferrin Drugs 0.000 claims description 6
- 239000006185 dispersion Substances 0.000 claims description 5
- 230000001804 emulsifying effect Effects 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 4
- 235000003642 hunger Nutrition 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- -1 DHA 0.43- 0.50g Chemical class 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 230000009469 supplementation Effects 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 2
- 230000012010 growth Effects 0.000 abstract description 10
- 235000015097 nutrients Nutrition 0.000 abstract description 7
- 230000003647 oxidation Effects 0.000 abstract description 5
- 238000007254 oxidation reaction Methods 0.000 abstract description 5
- 240000007049 Juglans regia Species 0.000 abstract 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 17
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 17
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 17
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 16
- 239000011782 vitamin Substances 0.000 description 16
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 14
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 14
- 229940088594 vitamin Drugs 0.000 description 13
- 229930003231 vitamin Natural products 0.000 description 13
- 235000013343 vitamin Nutrition 0.000 description 13
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 12
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 12
- 150000003722 vitamin derivatives Chemical class 0.000 description 12
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 10
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 10
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical class OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 10
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 235000019197 fats Nutrition 0.000 description 9
- 229960003512 nicotinic acid Drugs 0.000 description 9
- 229960002477 riboflavin Drugs 0.000 description 9
- 102000004407 Lactalbumin Human genes 0.000 description 8
- 108090000942 Lactalbumin Proteins 0.000 description 8
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 235000019152 folic acid Nutrition 0.000 description 8
- 239000011724 folic acid Substances 0.000 description 8
- 229960000304 folic acid Drugs 0.000 description 8
- 235000001968 nicotinic acid Nutrition 0.000 description 8
- 239000011664 nicotinic acid Substances 0.000 description 8
- 235000019192 riboflavin Nutrition 0.000 description 8
- 239000002151 riboflavin Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 229910000019 calcium carbonate Inorganic materials 0.000 description 7
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 7
- 235000007144 ferric diphosphate Nutrition 0.000 description 7
- 239000011706 ferric diphosphate Substances 0.000 description 7
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 description 7
- 229940036404 ferric pyrophosphate Drugs 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 229960001471 sodium selenite Drugs 0.000 description 7
- 239000011781 sodium selenite Substances 0.000 description 7
- 235000015921 sodium selenite Nutrition 0.000 description 7
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 7
- 239000011747 thiamine hydrochloride Substances 0.000 description 7
- 229960000344 thiamine hydrochloride Drugs 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 235000010323 ascorbic acid Nutrition 0.000 description 6
- 229960005070 ascorbic acid Drugs 0.000 description 6
- 239000011668 ascorbic acid Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 235000000639 cyanocobalamin Nutrition 0.000 description 6
- 239000011666 cyanocobalamin Substances 0.000 description 6
- 229960002104 cyanocobalamin Drugs 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 229930003451 Vitamin B1 Natural products 0.000 description 5
- 229960003495 thiamine Drugs 0.000 description 5
- 235000010374 vitamin B1 Nutrition 0.000 description 5
- 239000011691 vitamin B1 Substances 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000008774 maternal effect Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 235000019155 vitamin A Nutrition 0.000 description 4
- 239000011719 vitamin A Substances 0.000 description 4
- 239000011647 vitamin D3 Substances 0.000 description 4
- 229940045997 vitamin a Drugs 0.000 description 4
- 239000011576 zinc lactate Substances 0.000 description 4
- 229940050168 zinc lactate Drugs 0.000 description 4
- 235000000193 zinc lactate Nutrition 0.000 description 4
- GDSOZVZXVXTJMI-SNAWJCMRSA-N (e)-1-methylbut-1-ene-1,2,4-tricarboxylic acid Chemical compound OC(=O)C(/C)=C(C(O)=O)\CCC(O)=O GDSOZVZXVXTJMI-SNAWJCMRSA-N 0.000 description 3
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 238000013098 chemical test method Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 3
- 238000013031 physical testing Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000001749 antrachitic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 235000001497 healthy food Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000020997 lean meat Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 235000008935 nutritious Nutrition 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001107 psychogenic effect Effects 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229940091258 selenium supplement Drugs 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 229940046010 vitamin k Drugs 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 238000004260 weight control Methods 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- LFDGRWDETVOGDT-UHFFFAOYSA-N 1h-pyrrole;hydrochloride Chemical compound Cl.C=1C=CNC=1 LFDGRWDETVOGDT-UHFFFAOYSA-N 0.000 description 1
- BHWMZEPWQUFLLQ-UHFFFAOYSA-N 2-hydroxypropanoic acid;zinc Chemical compound [Zn].CC(O)C(O)=O BHWMZEPWQUFLLQ-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical group NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical group NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000030538 Thecla Species 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003761 Vitamin B9 Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000003026 anti-oxygenic effect Effects 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- ZGRKFKYTCMLCCF-UHFFFAOYSA-N cobalt;oxalonitrile Chemical compound [Co].N#CC#N ZGRKFKYTCMLCCF-UHFFFAOYSA-N 0.000 description 1
- 238000004939 coking Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000011162 core material Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000035194 endochondral ossification Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 235000008085 high protein diet Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 235000021125 infant nutrition Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000032724 odontogenesis Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 235000021085 polyunsaturated fats Nutrition 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 125000002640 tocopherol group Chemical group 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019159 vitamin B9 Nutrition 0.000 description 1
- 239000011727 vitamin B9 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
- A23L25/30—Mashed or comminuted products, e.g. pulp, pastes, meal, powders; Products made therefrom, e.g. blocks, flakes, snacks; Liquid or semi-liquid products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本发明涉及一种微胶囊粉以及利用该微胶囊粉制备的乳母营养补充食品,该食品能够对乳母提供均衡的多元不饱和脂肪酸,保证乳母和成长中的婴儿的营养需求,微胶囊粉,包括:核桃仁45~55份、BiPRO90%乳清蛋白粉16~19份、伊代欣糖14~17份、L‑阿拉伯糖5~7份、共轭亚油酸6~9份、环状糊精3.2~3.5份、抗性糊精1~2份、海藻糖2~4份、维生素C类物质0.01~0.03份、维生素E0.01~0.03份。本发明还提供上述微胶囊粉以及乳母营养补充食品的制备方法,能够有效防止食品中所含不饱和脂肪酸等营养素的氧化,延长保质期达到15~18个月。
Description
技术领域
本发明属于食品加工技术领域,具体涉及一种微胶囊粉、乳母营养补充食品及其制备方法。
背景技术
产妇在生产之后,随即会转换角色成为哺乳期妇女,根据标准GB31601-2015,称其为乳母,哺乳期对于乳母的营养及婴儿的生长均是特殊的生理时期,因为出生6个月内的婴儿生长发育所需的各种营养素均来自于母体,乳母本身需要足够的营养恢复生育造成的身体机能下降,因此,重视哺乳期的营养状况,强化乳母营养,对于乳母以及婴儿的生长有着极其重要的作用。
核桃,作为大众喜爱且众所周知的高蛋白食物,常常被建议乳母多吃,而且会促进婴儿的大脑发育。但是,由于核桃食用之前,需要先剥去外层坚硬外壳,而剥壳的过程也是一个较为费劲的过程,导致核桃在平时食用中较为不便。为了方便大众食用,有商家将其剥壳处理,直接以核桃仁的形式售卖。但是,由于核桃的不饱和脂肪酸含量高达85~90%,多元不饱和脂肪酸可达70%以上,而多元不饱和脂肪酸的组成为长链的亚油酸和亚麻酸,极易被氧化产生哈喇味儿,虽然使用非化学抗氧化剂,有助于消除化学合成类添加剂(抗氧化剂)对人体的危害,但是常温下非化学抗氧化剂最长保质期至今还未突破9个月,这也使得高含量核桃亚油酸和亚麻酸难于用于乳母营养补充食品,保质期无法越过夏季高温。
目前国内外的乳母营养膳食食物中大多缺少多元不饱和脂肪酸,但是多元不饱和脂肪酸除了能够提供给乳母及婴儿均衡营养,同时,其中富含的天然的高含量核桃ω~6亚油酸和ω~3α~亚麻酸更是有助于婴儿大脑神经及视神经系统的发育。因此,提供一种富含多元不饱和脂肪酸并且具有较长保质期的乳母营养食品为目前亟待解决的技术问题。
发明内容
本发明一方面提供一种微胶囊粉以及利用该微胶囊粉制备的乳母营养补充食品,该食品以核桃仁为主要原料制成,能够对乳母提供均衡的多元不饱和脂肪酸,保证乳母和成长中的婴儿的营养需求。
本发明另一方面提供上述微胶囊粉以及乳母营养补充食品的制备方法,能够有效防止食品中所含多元不饱和脂肪酸的氧化,延长保质期达到15~18个月。
本发明的技术方案为:
一种微胶囊粉,以重量份数计,原料包括:
核桃仁45~55份、BiPRO90%乳清蛋白粉16~19份、伊代欣糖14~17份、L-阿拉伯糖5~7份、共轭亚油酸6~9份、环状糊精3.2~3.5份、抗性糊精1~2份、海藻糖2~4份、维生素C类物质0.01~0.03份、维生素E0.01~0.03份。
进一步地,以重量份数计,原料包括:
核桃仁48~52份、BiPRO90%乳清蛋白粉17~18份、伊代欣糖15~16份、L-阿拉伯糖5.5~6.5份、共轭亚油酸7~8份、环状糊精3.3~3.4份、抗性糊精1.4~1.7份、海藻糖2.5~3.5份、维生素C类物质0.015~0.025份、维生素E0.015~0.025份。
本发明提供的一种乳母营养补充食品,利用权利要求1或2所述的微胶囊粉与食品中可添加的食用营养素物质混合制成,以重量份数计,每100份所述乳母营养补充食品中,包括所述微胶囊粉94.15~94.735份,所述食用营养素物质包括:
进一步地,以重量份数计,每100份所述乳母营养补充食品中,包括所述微胶囊粉94.27~94.59份,所述营养类物质包括:
进一步地,所述乳母营养补充食品,每100g中含蛋白质20~22g、乳铁蛋白25~35mg、免疫球蛋白IG220~300mg,不饱脂肪酸26~28g,其中多元不饱和脂肪酸21~32g,包括DHA 0.43-0.50g,亚麻酸3.2~3.6g,亚油酸14~16g;
所述亚麻酸和亚油酸类的质量比为1:(3.8-4.6)。
本发明提供的一种微胶囊粉的制备方法,使用上述的微胶囊粉中的原料进行制备,包括以下步骤:
将所述份数的核桃仁加入3~5倍重量份的70℃~85℃的纯净水中研磨得到细度120~130目的浆液A;
将所述份数的BiPRO90%乳清蛋白粉、L-阿拉伯糖、共轭亚油酸、环状糊精、抗性糊精、海藻糖加入2倍重量份数的65℃~70℃的纯净水中溶解并研磨得到细度100~120目的浆液B;
将所述份数的维生素C类物质和维生素E混合后加入10倍重量份的所述浆液A混合乳化得到浆液C:
将所述浆液B和剩余的浆液A混合,并通过加热设备加热升温至94℃后停止加热,所述第二混合物继续升温至最高温度95℃,保温10~20min后对其降温至60℃,之后向降温混合物中均匀喷洒所述浆液C,搅拌均匀得到浆液D;
将所述浆液D经高压均质、高压喷雾干燥、过滤,降温冷却至30℃或以下温度后,制得所述微胶囊粉。
进一步地,所述混合乳化得到浆液C的过程中,使用高速剪切机进行乳化分散,其中所述高速剪切机的的转速控制为1150转/分~1200转/分。
进一步地,所述均匀喷洒浆液C搅拌均匀得到浆液D的过程中,搅拌时间为5~8min。
进一步地,将所述浆液D进行高压均质、高压喷雾干燥过程中,所述高压均质连续进行三次,三次的压力分别为10~20MPa、20~30MPa、20~30MPa;
所述高压喷雾干燥过程中,喷雾的进风温度为140℃~175℃,喷雾压力为5~20MPa,在喷雾干燥塔顶的瞬间升温速度为150℃/min;排风温度为95℃~110℃,在喷雾干燥塔顶的瞬间降温速度为30℃/min。
本发明提供的一种乳母营养补充食品的制备方法,将上述微胶囊粉与食用营养素物质通过混合机混合,制得所述乳母营养补充食品。
本发明公开的技术效果为:
(1)本发明以核桃仁和最接近母乳化蛋白的BiPRO90%浓缩乳清蛋白粉为主要原料,其中,乳清蛋白粉中富含β-球蛋白、α-乳白蛋白、免疫球蛋白、乳铁蛋白;特别适合作为乳母营养补充食品,具有通过母乳营养有益于婴幼儿大脑和神经系统形成、促进生育发展和提高乳母免疫力,核桃中大量的单不饱和和多不饱和脂肪酸,在补充蛋白的同时不会造成脂肪的堆积,保持体形。另外乳清蛋白可以加速体内胆固醇的代谢同时抑制胆固醇的合成,可以提高机体的免疫力,改善产后身体机能的下降。
(2)本发明添加的BiPRO90%浓缩乳清蛋白、伊代欣糖、低聚果糖等功能营养原料,使得产品具备补充乳母所需的必需营养素外,由于伊代欣糖的作用有利于控制体重和后期控制血糖的升高,低聚果糖的益生元作用有利于乳母后期保持润肠通便的顺利。
(3)本发明提供的制备方法方法,能够有效的防止核桃乳清蛋白复合粉所含不饱和脂肪酸等营养素(芯材)的氧化,延长保质期达到15~18个月。
(4)本发明提供的乳母营养补充食物中每100克含有蛋白质19~21g,钙含量1.34g,DHA藻油含量450mg,。
(5)本发明中的核桃与乳清蛋白以及其它原料的相互作用下制得的乳母营养补充食品营养丰富全面,婴儿通过吸收乳母摄入的营养物质,有益于其大脑和神经系统形成,同时能够提高乳母免疫力,核桃中大量的单不饱和脂肪酸和多不饱和脂肪酸,在补充蛋白的同时不会造成脂肪的堆积,保持体形。另外乳清蛋白可以加速体内胆固醇的代谢同时抑制胆固醇的合成,可以提高机体的免疫力,改善乳母产后身体机能的下降,对于确保乳母和婴儿的健康都有十分重要的意义。
附图说明
构成本申请的一部分的说明书附图用来提供对本发明的进一步理解,本发明的示意性实施例及其说明用于解释本发明,并不构成对本发明的不当限定。其中:
图1为本发明提供的用以制备乳母营养食品的微胶囊粉的制备流程图。
具体实施方式
下面将参考附图并结合实施例来详细说明本发明。各个示例通过本发明的解释的方式提供而非限制本发明。实际上,本领域的技术人员将清楚,在不脱离本发明的范围或精神的情况下,可在本发明中进行修改和变型。例如,示为或描述为一个实施例的一部分的特征可用于另一个实施例,以产生又一个实施例。因此,所期望的是,本发明包含归入所附权利要求及其等同物的范围内的此类修改和变型。
一种乳母营养补充食品,由特制的微胶囊粉与食品中可添加的食用营养素物质混合制成,其中,以重量份数计,每100份所述乳母营养补充食品中,微胶囊粉占94.15~94.735份,余量为食用营养素物质。
其中的微胶囊粉是根据微粉胶囊工艺制成,具体原料,以重量份数计,包括:核桃仁45~55份、BiPRO90%乳清蛋白粉16~19份、伊代欣糖14~17份、L-阿拉伯糖5~7份、共轭亚油酸6~9份、环状糊精3.2~3.5份、抗性糊精1~2份、海藻糖2~4份、维生素C类物质0.01~0.03份、维生素E0.01~0.03份。
核桃仁含有丰富的营养素,含有多种植物脂肪,富含蛋白质、多元不饱和脂肪酸、维生素E,碳水化合物;并含有人体必需的钙、磷、铁、镁、硒等多种微量元素和矿物质,以及胡萝卜素、核黄素、维生素B1等多种维生素。现代医学研究证明核桃仁富含α~亚麻酸和ω~6亚油酸类具有健脑益智等多种作用,对幼童生长及人体一生健康有益。
BiPRO90%乳清蛋白粉,是采用先进工艺从牛奶分离提取出来的珍贵蛋白质,以其纯度高、吸收率高、氨基酸组成最合理等诸多优势被推为“蛋白之王”。乳清蛋白不但容易消化,而且还具有高生物价、高效化率、高蛋白质功效比和高利用率,是蛋白质中的精品。含有人体所需的所有必需氨基酸,其氨基酸组成模式与骨骼肌中的氨基酸组成模式几乎完全一致,极其容易被人体所吸收。主要成分为,β~球蛋白、α~乳白蛋白、免疫球蛋白、乳铁蛋白。该乳清蛋白粉与同类相比的营养优势在于其每百克含有活性蛋白:乳铁蛋白168~180mg与免疫球蛋白IG1.6~2克。乳铁蛋白是一种天然的机体免疫调节剂,是婴幼儿童成长不可或缺的免疫蛋白,有助于改善婴幼儿童营养状况,降低婴幼儿童腹泻、呼吸道疾病、败血症等疾病的发病风险。免疫球蛋白IG是动物体内的重要免疫活性物质,在动物的营养代谢和生理调节方面具有重要作用,对于婴幼儿童抗感染具有重要意义。其是机体黏膜局部免疫的主要因素。
伊代欣糖(异麦芽酮糖),是通过现代生物技术,从甘蔗、蜂蜜等产品中发现的一种天然糖类,异麦芽酮糖摄取不会被唾液、胃酸和胰液消化,一直到小肠才被水解成葡萄糖和果糖吸收。由于分解十分缓慢,所以使人体对糖的吸收和利用达到了平衡,不会使血糖浓度提高。所以有利于控制乳母中后期的血糖升高及准糖尿病乳母。因为异麦芽酮糖被消化吸收后不会引起胰岛素的分泌,也就不会引起LPL活性的激活作用。所以异麦芽酮糖的存在使得油脂不容易被吸收至脂肪组织中。故有利于控制乳母中后期的体重迅速增加。异麦芽酮糖可被人体缓慢消化和吸收,因为它在小肠内完全分解与吸收。所以具有防止腹泻的效果。
L-阿拉伯糖,是蔗糖消化酶的非竞争性抑制剂,人体食用后可抑制肠道内蔗糖酶的活性,使摄入的蔗糖不被人体吸收,进而影响餐后血糖和甘油三酯(三酰甘油)的合成,从而抑制身体脂肪堆积,因而可被用于防治肥胖、高血压、高血脂等疾病。当蔗糖中加入2%-3%L-阿拉伯糖,可以抑制60%-70%蔗糖的吸收,同时也抑制了血糖值少升高约50%。美国医疗协会将其列入用做抗肥胖剂的营养补充剂或非处方药,在日本厚生省的特定保健用食品清单中,L-阿拉伯糖被列入用于调节血糖的专用特殊保健食品添加剂,我国卫生部在2008年5月将L-阿拉伯糖列为新资源食品。
共轭亚油酸,作为一种新发现的营养素,目前在欧美的健康食品界,几乎已经成了预防现代文明病的万灵丹,从抗癌到预防心血管疾病、糖尿病,到体重控制上,几乎是生活在二十一世纪现代人不可或缺的健康食品。CLA在体重控制上的卓越表现,可以有效的降低体内脂肪组织相对于瘦肉组织的比率,真正的减到肥肉,而使瘦肉比率上升,这样的好处是瘦肉越多,体内新陈代谢能力越高,于是形成良性循环,减肥将更容易达到目标。
抗性糊精,为白色到淡黄色粉末,是以非转基因玉米淀粉为原料,经过一定程度的水解、聚合、分离等步骤制成的一种水溶性膳食纤维。具有热量低,溶解性好,微甜无异味。可用于在食品、饮料、制粉微胶囊等加工产品中。研究表明,抗性糊精是集调节肠道健康、具有益生元效益等多种功效。
海藻糖,是由两个葡萄糖分子以α,α~1,1键连接成的非还原性的双糖,是一种安全可靠的天然糖类,具有优异的保持细胞活力和生物大分子活性的特性,在科学界素有“生命之糖”的美誉。可作为防止食品劣化、抑制营养素变质,保持食品新鲜风味、提升食品品质的独特食品配料。海藻糖对多种生物具有非特异性保护作用。
维生素E,是一种脂溶性维生素,其水解产物为生育酚,具备良好的抗氧化性能。溶于脂肪和乙醇等有机溶剂中,不溶于水,对热、酸稳定,对碱不稳定,对氧敏感,对热不敏感。生育酚能促进性激素分泌;使女子雌性激素浓度增高,提高生育能力,预防流产等。近来还发现可抑制眼睛晶状体内的过氧化脂反应,使末梢血管扩张,改善血液循环,预防近视眼发生和发展。
其中的食用营养素物质包括:碳酸钙4.3份~4.5份、焦磷酸铁0.33份~0.36份、乳酸锌0.11份~0.13份、亚硒酸钠0.0003~0.0005份、醋酸维生素A0.15份~0.25份、维生素D30.007份~0.009份、盐酸硫胺素0.003份~0.005份、烟酸0.037份~0.038份、盐酸吡哆醇0.005份~0.007份、植物甲奈醌0.002份~0.004份、核黄素0.03份~0.04份、叶酸0.07份~0.09份、氰钴胺0.0007份~0.0009份、L~抗坏血酸0.18份~0.36份、DHA藻油0.04份~0.06份。
碳酸钙为食品提供钙,焦磷酸铁为铁的来源,乳酸锌为锌的来源,其中,
亚硒酸钠,营养强化剂硒的来源之一,是人体必需的微量元素,是人体内的抗氧化剂,清除人体内过多的氧自由基,防止细胞膜脂质过氧化的破坏,能提高人体免疫力,减低血脂、血压,防止动脉粥样硬化。
醋酸维生素A,为维生素A的一种,在婴幼儿成长发育的过程中,具有重要的作用。例如,对维持上皮细胞的完整性有着至关重要的作用,如果体内缺乏维生素A,会导致皮肤干燥、抵抗力下降等症状,此外,维生素A有助于巨噬细胞、T细胞和抗体的产生,增强婴幼儿抗御疟疾的能力。维生素A对促进婴幼儿骨骼生长同样意义重大,当婴幼儿体内缺乏维生素A时,骨组织将会发生变性,软骨内骨化过程将会放慢或停止,使孩子发育迟缓,牙齿发育缓慢、不良。
维生素D3,是维生素D的一种,是一种脂溶性维生素,也被看作是一种作用于钙、磷代谢的激素前体,具抗佝偻病作用,又称抗佝偻病维生素,维持血清钙磷浓度的稳定,促进生长和骨骼钙化,促进牙齿健全,帮助婴幼儿童吸收钙磷等微量元素。
盐酸硫胺素,是维生素B1的一种,被称为精神性的维生素,这是因为维生素B1对神经组织和精神状态有良好的影响。
烟酸,也称作维生素B3,或维生素PP,它是人体必需的13种维生素之一,是一种水溶性维生素,属于维生素B族。烟酸在人体内转化为烟酰胺,烟酰胺是辅酶Ⅰ和辅酶Ⅱ的组成部分,参与体内脂质代谢,组织呼吸的氧化过程和糖类无氧分解的过程。
盐酸吡哆醇,维生素B1的一种,被称为精神性的维生素,这是因为维生素B1对神经组织和精神状态有良好的影响。
植物甲奈醌,维生素K的一种,维生素K是具有叶绿醌生物活性的一类物质,是脂溶性维生素,防止婴幼儿出血疾病,预防内出血及痔疮,减少生理期大量出血,促进血液正常凝固。
核黄素,维生素B2的一种,是一种水溶性维生素,可以促进发育和细胞的再生;促使皮肤、指甲、毛发的正常生长;帮助预防和消除口腔内、唇、舌及皮肤的炎反应,统称为口腔生殖综合症;增进视力,减轻眼睛的疲劳;影响人体对铁的吸收;与其他物质结合一起,从而影响生物氧化和能量代谢。
叶酸,也叫维生素B9,是一种水溶性维生素。是人体在利用糖分和氨基酸时的必要物质,是机体细胞生长和繁殖所必需的物质。
氰钴胺,维生素B12的一种,作为甲基转移酶的辅因子,参与蛋氨酸、胸腺嘧啶等的合成,保护叶酸在细胞内的转移和贮存;代谢脂肪酸,使脂肪、碳水化合物、蛋白质被身体适当运用;消除烦躁不安,集中注意力,增强记忆及平衡感;是神经系统功能健全不可缺少的维生素,参与神经组织中一种脂蛋白的形成。
DHA藻油,二十二碳六烯酸,俗称脑黄金,是一种对人体非常重要的多不饱和脂肪酸,属于Omega~3不饱和脂肪酸家族中的重要成员。DHA是神经系统细胞生长及维持的一种主要元素,是大脑和视网膜的重要构成脂肪酸,在人体大脑皮层中含量高达20%,在眼睛视网膜中所占比例最大,约占50%。对婴儿智力和视力发育至关重要。DHA藻油提取自海洋微藻,未经食物链的传递,相对更安全。
在本发明的一个优选实施方式中,其中的微胶囊粉,以重量份数计,原料包括48~52份、BiPRO90%乳清蛋白粉17~18份、伊代欣糖15~16份、L-阿拉伯糖5.5~6.5份、共轭亚油酸7~8份、环状糊精3.3~3.4份、抗性糊精1.4~1.7份、海藻糖2.5~3.5份、维生素C类物质0.015~0.025份、维生素E0.015~0.025份。
在本发明的一个优选实施方式中,食用营养素物质包括:碳酸钙4.35份~4.45份、焦磷酸铁0.34~0.35份、乳酸锌0.115~0.125份、亚硒酸钠0.00035~0.00045份、醋酸维生素A0.18份~0.23份、维生素D30.0075份~0.0085份、盐酸硫胺素0.0035份~0.0045份、烟酸0.0373份~0.0378份、盐酸吡哆醇0.0055份~0.0065份、植物甲奈醌0.0025份~0.0035份、核黄素0.033份~0.037份、叶酸0.075份~0.085份、氰钴胺0.00075份~0.00085份、L~抗坏血酸0.22份~0.33份、DHA藻油0.044份~0.056份。
在本发明的一个实施方式中,乳母营养补充食品,每100g中含蛋白质20~22g、乳铁蛋白25~35mg、免疫球蛋白IG220~300mg,不饱脂肪酸26~28g,其中多元不饱和脂肪酸21~32g,包括DHA 0.43-0.50g,亚麻酸3.2~3.6g,亚油酸14~16g;所述亚麻酸和亚油酸类的质量比为1:(3.8-4.6)。
本发明提供的微胶囊粉的制备方法,利用上述微胶囊粉中的设定重量份数的原料制备,如图1所示,具体制备方法如下:
步骤1、将所述份数的核桃仁加入3~5倍重量份的70℃~85℃的纯净水中研磨得到细度120~130目的浆液A;
步骤2、将所述份数的BiPRO乳清蛋白粉、L-阿拉伯糖、共轭亚油酸、环状糊精、抗性糊精、海藻糖加入2倍重量份数的65℃~70℃的纯净水中溶解并研磨得到细度100~120目的浆液B;
步骤3、将所述份数的维生素C类物质和维生素E混合后加入10倍重量份的所述浆液A混合乳化得到浆液C;
本发明的一个具体实施方式中,将第一混合物与浆液A混合乳化分散时,优选采用高速剪切机进行乳化彻底溶解及分散,高速剪切机的的转速控制为1150转/分~1200转/分,得到浆液C。
步骤4、将所述浆液B和剩余的浆液A混合,并通过加热设备加热升温至94℃后停止加热,所述第二混合物继续升温至最高温度95℃,保温10~20min后对其降温至60℃,之后向降温混合物中均匀喷洒所述浆液C,搅拌均匀得到浆液D;
本发明的一个具体实施方式中,向降温混合物中均匀喷洒浆液C时,需要同时进行搅拌,搅拌过程过长,导致混合物降温过低,不利于后续的高压均质和高压喷雾,搅拌时间过短,可能导致搅拌不均匀,本实施方式中优选搅拌时间为5~8min,最佳时间为5min。
步骤5、将所述浆液D经高压均质、高压喷雾干燥、过滤,降温冷却至30℃或以下温度后,制得所述微胶囊粉。
本发明的一个具体实施方式中,为了提高均质效果,将浆液D进行高压均质时,优选高压均质连续进行三次,三次的压力分别为15±5MPa、25±5MPa、25±5MPa;高压喷雾干燥过程中,控制喷雾的进风温度为140℃-175℃,喷雾压力控制为10-20MPa,塔顶温度的波动与热力蒸汽和环境风温度、风速有关,当塔顶的温度较高时,甚至达到175℃时,则需要降低喷雾压力为10-14MPa,当塔顶的温度较低时,比如达到140-145℃,则需要调高喷雾压力至18-20MPa,通过该方法控制在整个生产过程中微胶囊粉形成的粒度基本一致,相反,如果喷雾压力超出该压力范围,则会导致微胶囊粉粒度不一致,需要杜绝。根据标准生产工艺,排风温度控制为95℃-110℃,控制喷雾干燥塔顶的瞬间升温速度为150℃/min,在喷雾干燥塔顶的瞬间降温速度为30℃/min。当排风温度过高,或者升温降温速度过快,则会导致制成的微胶囊粉焦化,而升温降温速度过慢,生产能效较低。
喷雾干燥结束后,得到致密的玻璃化体干燥结晶膜胶粒G,将结晶膜胶粒G过120目筛,降温冷却至30℃或以下温度后,制得微胶囊粉。
本发明提供的乳母营养补充食品的制备方法,是将前述微胶囊粉与食用营养素物质通过精密混合机混合,制得所述乳母营养补充食品。
在混合时,优选采用三维粉体混合机进行混合。
下面通过具体实施例进一步详细说明本发明提供的微胶囊粉以及由该微胶囊粉制成的乳母营养补充食品。
实施例1
乳母营养补充食品用微胶囊粉,原料包括:核桃仁55g、BiPRO90%乳清蛋白粉19g、伊代欣糖17g、L-阿拉伯糖7g、共轭亚油酸9g、环状糊精3.5g、抗性糊精2g、海藻糖4g、L-抗坏血酸棕榈酸酯0.03g、维生素E0.03g。
利用上述微胶囊粉制成的乳母营养补充食品,每100g粉料包括:
上述微胶囊粉94.735g、碳酸钙4.3g;焦磷酸铁0.33g;乳酸锌0.11g;亚硒酸钠0.0003份、醋酸维生素A0.15份、维生素D30.007份、盐酸硫胺素0.003份、烟酸0.037份、盐酸吡哆醇0.005份、植物甲奈醌0.002份、核黄素0.03份、叶酸0.07份、氰钴胺0.0007份、L~抗坏血酸0.18份、DHA藻油0.04份。
其制备方法为:
(1)将55g核桃仁与165mL、70℃的纯净水混合研磨得到细度120目的浆液A;
(2)将BiPRO90%乳清蛋白粉19g、伊代欣糖17g、L-阿拉伯糖7g、共轭亚油酸9g、环状糊精3.5g、抗性糊精2g、海藻糖4g加入46.2mL的65℃的纯净水进行研磨得到细度100目的浆液B;
(3)将0.03gL-抗坏血酸和0.03g维生素E混合后加入0.6g的浆液A,充分搅拌并用高速剪切机乳化彻底溶解及分散,控制高速剪切机的转速为1150转/分,得到浆液C;
(4)将余量的219.4g浆液A和92.4g浆液B混合,边搅拌边加热,升温至94℃后,在92~95℃条件下保持20min后,降温至60℃,然后加入浆液C继续搅拌5min,得到浆液D,在喷雾干燥塔顶瞬间升温速度为150℃/min,塔内降温速度为30℃/min;
(5)将得到的浆液D依次进行三次高压均质,均质压力分别为15MPa、25MPa、25MPa,再进行高压喷雾干燥,喷雾压力为5MPa、进风温度140℃、排风温度95℃,之后过滤,降温冷却至30℃,制得用于孕妇营养品的核桃乳清蛋白微胶囊粉。
(6)将上述获得的微胶囊粉用GMP精密混合机与碳酸钙4.3g;焦磷酸铁0.33g;乳酸锌0.11g;亚硒酸钠0.0003份、醋酸维生素A0.15份、维生素D30.007份、盐酸硫胺素0.003份、烟酸0.037份、盐酸吡哆醇0.005份、植物甲奈醌0.002份、核黄素0.03份、叶酸0.07份、氰钴胺0.0007份、L~抗坏血酸0.18份、DHA藻油0.04份精密混合,制成孕妇营养补充食品。
对实施例1提供的乳母营养补充食品进行SGS检测,其微生物测试结果如下:(每日份为40g)
对实施例1提供的乳母营养补充食品进行SGS检测,其理化测试结果(一)如下:
计算测试结果:
计算项目 | 单位 | 计算方法 | 计算结果 |
碳水化合物 | g/100g | GB/Z 21922~2008 | 42.0 |
能量 | KJ/100g | GB/Z 21922~2008 | 2183 |
理化测试结果(二):
从上述检测结果看以看到,本发明提供的乳母营养补充食品,每100g中含总脂肪酸为29.79g,多元不饱和脂肪酸21.74g,多元不饱和脂肪酸含量占总脂肪酸量的72.978%,其中亚油酸占总脂肪酸的48.9%,每100g营养补充食品中,DHA含量为450mg,亚麻酸的含量为3.33%,通过计算得到每100g营养补充食品中亚油酸的含量为14.57g,亚麻酸的含量为3.33g则,该营养补充食品中,不饱和脂肪酸亚麻酸和亚油酸的质量比为1:4.37。
实施例2
乳母营养补充食品用微胶囊粉,原料包括:核桃仁45g、BiPRO90%乳清蛋白粉16g、伊代欣糖14g、L-阿拉伯糖5g、共轭亚油酸6g、环状糊精3.2g、抗性糊精1g、海藻糖2g、L-抗坏血酸棕榈酸酯0.01g、维生素E0.01g。
利用上述微胶囊粉制成的乳母营养补充食品,每100g粉料包括:
上述微胶囊粉94.15g、碳酸钙4.5g、焦磷酸铁0.36g、乳酸锌0.13g、亚硒酸钠0.0005g、醋酸维生素A0.25g、维生素D30.009g、盐酸硫胺素0.005g、烟酸0.038g、盐酸吡哆醇0.007g、植物甲奈醌0.004g、核黄素0.04g、叶酸0.09g、氰钴胺0.0009g、L~抗坏血酸0.36g、DHA藻油0.06g。
其制备方法为:
(1)将45g核桃仁与135mL、85℃的纯净水混合研磨得到细度120目的浆液A;
(2)将BiPRO90%乳清蛋白粉16g、伊代欣糖14g、L-阿拉伯糖5g、共轭亚油酸6g、环状糊精3.2g、抗性糊精1g、海藻糖2g加入47.2mL的65℃的纯净水进行研磨得到细度100目的浆液B;
(3)将0.01gL-抗坏血酸棕榈酸酯和0.01g维生素E混合后,然后加入0.2g的浆液A,充分搅拌并用高速剪切机乳化彻底溶解及分散,控制高速剪切机的转速为1150转/分,得到浆液C;
(4)将余量的179.8g浆液A和94.4g浆液B混合,边搅拌边加热,升温至94℃后,在92~95℃条件下保持20min后,降温至60℃,然后加入浆液C继续搅拌5min,得到浆液D,在喷雾干燥塔顶瞬间升温速度为150℃/min,塔内降温速度为30℃/min;
(5)将得到的浆液D依次进行三次高压均质,均质压力分别为15MPa、25MPa、25MPa,再进行高压喷雾干燥,喷雾压力为5MPa、进风温度140℃、排风温度95℃,之后过滤,降温冷却至30℃,制得用于孕妇营养品的核桃乳清蛋白微胶囊粉。
(6)将上述获得的微胶囊粉用GMP精密混合机与碳酸钙4.5g、焦磷酸铁0.36g、乳酸锌0.13g、亚硒酸钠0.0005g、醋酸维生素A0.25g、维生素D30.009g、盐酸硫胺素0.005g、烟酸0.038g、盐酸吡哆醇0.007g、植物甲奈醌0.004g、核黄素0.04g、叶酸0.09g、氰钴胺0.0009g、L~抗坏血酸0.36g、DHA藻油0.06g精密混合,制成孕妇营养补充食品。
对实施例2提供的乳母营养补充食品进行SGS检测,其理化测试结果如下:(每日份为40g)
理化检测的结果(二)如下:(每日份为40g)
从上述检测结果看以看到,本发明提供的乳母营养补充食品,每100g中含总脂肪酸为27.71g,多元不饱和脂肪酸18.22g,多元不饱和脂肪酸含量占总脂肪酸量的65.75%,其中亚油酸占总脂肪酸的52.5%,每100g营养补充食品中,DHA含量为0.47g,亚麻酸的含量为3.2,亚油酸的含量为14.54,该营养补充食品中,不饱和脂肪酸亚麻酸和亚油酸的质量比为1:4.54。
本发明以富含不饱和脂肪酸的核桃仁和最接近母乳化蛋白的乳清蛋白粉为主要原料,赋予产品动植物双蛋白的营养元素,用微胶囊技术制得富含不饱和脂肪酸质量稳定的核桃基础粉,添加了相应的维生素和矿物质元素作为微量元素,制得营养全面丰富的儿童营养补充品。同时本发明添加了结晶果糖、海藻糖、紫苏油、DHA等功能性原料,产品除了补充儿童所需的基本营养素外,其中天然的高含量核桃亚油酸和α~亚麻酸更是有助于幼童大脑神经及视神经系统的发育。
以上仅为本发明的优选实施例,并不用于限制本发明,对于本领域的技术人员来说,本发明可以有各种更改和变化。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种微胶囊粉,其特征在于,以重量份数计,原料包括:
核桃仁45~55份、BiPRO90%乳清蛋白粉16~19份、伊代欣糖14~17份、L-阿拉伯糖5~7份、共轭亚油酸6~9份、环状糊精3.2~3.5份、抗性糊精1~2份、海藻糖2~4份、维生素C类物质0.01~0.03份、维生素E0.01~0.03份。
2.根据权利要求1所述的微胶囊粉,其特征在于,以重量份数计,原料包括:
核桃仁48~52份、BiPRO90%乳清蛋白粉17~18份、伊代欣糖15~16份、L-阿拉伯糖5.5~6.5份、共轭亚油酸7~8份、环状糊精3.3~3.4份、抗性糊精1.4~1.7份、海藻糖2.5~3.5份、维生素C类物质0.015~0.025份、维生素E0.015~0.025份。
3.一种乳母营养补充食品,其特征在于,利用权利要求1或2所述的微胶囊粉与食品中可添加的食用营养素物质混合制成,以重量份数计,每100份所述乳母营养补充食品中,包括所述微胶囊粉94.15~94.735份,所述食用营养素物质包括:
4.根据权利要求3所述的乳母营养补充食品,其特征在于,
以重量份数计,每100份所述乳母营养补充食品中,包括所述微胶囊粉94.27~94.59份,所述营养类物质包括:
5.根据权利要求4所述的乳母营养补充食品,其特征在于,
所述乳母营养补充食品,每100g中含蛋白质20~22g、乳铁蛋白25~35mg、免疫球蛋白IG220~300mg,不饱脂肪酸26~28g,其中多元不饱和脂肪酸21~32g,包括DHA 0.43-0.50g,亚麻酸3.2~3.6g,亚油酸14~16g;
所述亚麻酸和亚油酸类的质量比为1:(3.8-4.6)。
6.一种微胶囊粉的制备方法,其特征在于,使用权利要求1或2所述的微胶囊粉中的原料进行制备,包括以下步骤:
将所述份数的核桃仁加入3~5倍重量份的70℃~85℃的纯净水中研磨得到细度120~130目的浆液A;
将所述份数的BiPRO90%乳清蛋白粉、L-阿拉伯糖、共轭亚油酸、环状糊精、抗性糊精、海藻糖加入2倍重量份数的65℃~70℃的纯净水中溶解并研磨得到细度100~120目的浆液B;
将所述份数的维生素C类物质和维生素E混合后加入10倍重量份的所述浆液A混合乳化得到浆液C:
将所述浆液B和剩余的浆液A混合,并通过加热设备加热升温至94℃后停止加热,所述第二混合物继续升温至最高温度95℃,保温10~20min后对其降温至60℃,之后向降温混合物中均匀喷洒所述浆液C,搅拌均匀得到浆液D;
将所述浆液D经高压均质、高压喷雾干燥、过滤,降温冷却至30℃或以下温度后,制得所述微胶囊粉。
7.根据权利要求6所述的方法,其特征在于,
所述混合乳化得到浆液C的过程中,使用高速剪切机进行乳化分散,其中所述高速剪切机的的转速控制为1150转/分~1200转/分。
8.根据权利要求6所述的方法,其特征在于,
所述均匀喷洒浆液C搅拌均匀得到浆液D的过程中,搅拌时间为5~8min。
9.根据权利要求6所述的方法,其特征在于,
将所述浆液D进行高压均质、高压喷雾干燥过程中,所述高压均质连续进行三次,三次的压力分别为10~20MPa、20~30MPa、20~30MPa;
所述高压喷雾干燥过程中,喷雾的进风温度为140℃~175℃,喷雾压力为5~20MPa,在喷雾干燥塔顶的瞬间升温速度为150℃/min;排风温度为95℃~110℃,在喷雾干燥塔顶的瞬间降温速度为30℃/min。
10.一种乳母营养补充食品的制备方法,其特征在于,将权利要求1或2所述微胶囊粉与权利要求3~5任一项中所述的食用营养素物质通过混合机混合,制得所述乳母营养补充食品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910067182.7A CN109601987A (zh) | 2019-01-24 | 2019-01-24 | 一种微胶囊粉、乳母营养补充食品及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910067182.7A CN109601987A (zh) | 2019-01-24 | 2019-01-24 | 一种微胶囊粉、乳母营养补充食品及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109601987A true CN109601987A (zh) | 2019-04-12 |
Family
ID=66018213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910067182.7A Pending CN109601987A (zh) | 2019-01-24 | 2019-01-24 | 一种微胶囊粉、乳母营养补充食品及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109601987A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113068763A (zh) * | 2021-03-23 | 2021-07-06 | 广州金酮医疗科技有限公司 | 一种低致敏乳蛋白的制备方法及包含低致敏乳蛋白的乳母营养组合物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1672541A (zh) * | 2005-04-21 | 2005-09-28 | 石家庄三鹿集团股份有限公司 | 一种惠孕奶粉 |
US20060088574A1 (en) * | 2004-10-25 | 2006-04-27 | Manning Paul B | Nutritional supplements |
US20160213040A1 (en) * | 2013-10-11 | 2016-07-28 | Abbott Laboratories | Nutritional composition for pregnant women with a beneficial glucose and insulin profile |
CN109123660A (zh) * | 2018-09-17 | 2019-01-04 | 山西欧莱特农业科技有限公司 | 一种用于孕妇营养品的核桃乳清蛋白复合粉及其制备方法 |
-
2019
- 2019-01-24 CN CN201910067182.7A patent/CN109601987A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060088574A1 (en) * | 2004-10-25 | 2006-04-27 | Manning Paul B | Nutritional supplements |
CN1672541A (zh) * | 2005-04-21 | 2005-09-28 | 石家庄三鹿集团股份有限公司 | 一种惠孕奶粉 |
US20160213040A1 (en) * | 2013-10-11 | 2016-07-28 | Abbott Laboratories | Nutritional composition for pregnant women with a beneficial glucose and insulin profile |
CN109123660A (zh) * | 2018-09-17 | 2019-01-04 | 山西欧莱特农业科技有限公司 | 一种用于孕妇营养品的核桃乳清蛋白复合粉及其制备方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113068763A (zh) * | 2021-03-23 | 2021-07-06 | 广州金酮医疗科技有限公司 | 一种低致敏乳蛋白的制备方法及包含低致敏乳蛋白的乳母营养组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102715240B (zh) | 生酮饮食配方奶及其制备方法 | |
CN105613789B (zh) | 一种高脂高膳食纤维复合动植物粉末油脂、其制备方法及应用 | |
CN111084381A (zh) | 生酮营养代餐粉及应用 | |
WO2016035095A1 (en) | Optimized nutrient food | |
CN107136511A (zh) | 一种促进脑神经发育的牡丹籽油组合物、牡丹籽油软胶囊及其制备方法 | |
CN109123660B (zh) | 一种用于孕妇营养品的核桃乳清蛋白复合粉及其制备方法 | |
CN107660620A (zh) | 一种羊基油脂微胶囊粉末及其制备方法 | |
CN111802476A (zh) | 一种提高儿童睡眠质量的奶粉及其制备方法 | |
JP2019503698A (ja) | コラーゲンを含む高カロリー、高タンパク質の栄養配合物 | |
CN109123659B (zh) | 一种用于辅食营养补充品的核桃蛋白复合粉及其制备方法 | |
CN103371318B (zh) | 一种膳食营养补充食品 | |
CN108703365A (zh) | 蛋白质过敏专用型临床营养配方及其制备方法 | |
CN107441217B (zh) | 一种富含α-亚麻酸的口服乳剂及其制备方法 | |
CN105432792A (zh) | 一种学龄前儿童基础营养奶粉、营养粉套装及制备方法 | |
CN109965273A (zh) | 一种小儿多动症专用型临床营养配方及其制备方法 | |
CN110179118A (zh) | 一种适用于婴幼儿的葵花籽营养调和油微胶囊及其制备方法 | |
CN105494577A (zh) | 学龄前儿童食用的营养易消化饼干 | |
CN108541912A (zh) | 一种抗氧化降血脂组合物及其制备方法和应用 | |
CN109601987A (zh) | 一种微胶囊粉、乳母营养补充食品及其制备方法 | |
CN110584120A (zh) | 骨健康组合物 | |
CN102511875A (zh) | 一种适合术后人群饮用的红枣浓浆 | |
CN102511858A (zh) | 一种适合孕妇食用的红枣浓浆及其生产工艺 | |
CN101703249A (zh) | 具有调节内分泌、提高免疫力作用的保健品及制备方法 | |
CN109601988A (zh) | 一种微胶囊粉、儿童营养补充食品及其制备方法 | |
CN109601986A (zh) | 一种微胶囊粉、孕妇营养补充食品及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190412 |